December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Nina Niu Sanford: Nice to see updated EASL guidelines for HCC now include RT
Dec 20, 2024, 23:21

Nina Niu Sanford: Nice to see updated EASL guidelines for HCC now include RT

Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, reshared a post by Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, on X:

“Nice to see updated EASL guidelines for HCC now include RT!

1 small technicality: guidelines refer to photon SBRT or proton RT Photons/protons are particle types, & SBRT refers to technique (high dose to tumor alone, precise setup..) In HCC, protons also often given as SBRT.”

Nina Niu Sanford: Nice to see updated EASL guidelines for HCC now include RT

Quoting Arndt Vogel‘s post:

“EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

  • Get the new guideline for HCC
  • Up to date, very granular recommendationNina Niu Sanford: Nice to see updated EASL guidelines for HCC now include RT

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

Nina Niu Sanford is an Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital. She specializes in treating gastrointestinal cancers and actively participates in clinical trials combining high-dose radiation therapy with immunotherapy. Additionally, she researches healthcare access disparities and conducts pan-cancer outcomes research using large databases.

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.